WO2001020332A1 - Procede de recherche d'une substance permettant de lutter contre le virus de la grippe - Google Patents
Procede de recherche d'une substance permettant de lutter contre le virus de la grippe Download PDFInfo
- Publication number
- WO2001020332A1 WO2001020332A1 PCT/JP2000/006255 JP0006255W WO0120332A1 WO 2001020332 A1 WO2001020332 A1 WO 2001020332A1 JP 0006255 W JP0006255 W JP 0006255W WO 0120332 A1 WO0120332 A1 WO 0120332A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- influenza virus
- miniplasmin
- substance
- virus
- searching
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the present invention relates to a method for searching for a substance having an anti-influenza virus activity.
- the first is to develop vaccines as substances with anti-influenza virus activity. Inactivated influenza vaccines and live vaccines have been developed.
- the second is a method of emitting Open explore the ion channel M 2 protein of influenza virus as a substance having anti fin full E stanza virus act Chiya down channel blockers that target.
- sialic acid is known to be the receptor on the membrane of cells infected with influenza virus
- sialic acid-targeted anti-influenza virus-active substance Is a way to explore and develop.
- the outer membrane glycoprotein of influenza virus is often recognized as an antigen. Therefore, the effect of the vaccine developed by this method could not always be expected.
- the searched how emits open the ion channel M 2 protein of the second influenza virus as a substance having anti-influenza virus activity of Chiya down channel blockers that target, for example, its effectiveness is broadcast as one of the conventional anti-Parkinson's disease drugs this is called amantadine, which is tell have been searched, to block M 2 protein
- amantadine which is tell have been searched
- the problem to be solved by the present invention is to provide a method capable of solving the drawbacks of the conventional technology and efficiently searching for a substance having an anti-influenza virus action based on a different action from the conventional technique. It is to be.
- miniplasmin The major influenza virus activator in Japan is miniplasmin, which means that miniplasmin is critically involved in the activation of influenza virus and Sendai virus, that is, influenza virus and Sendai virus They succeeded in finding that miniplasmin must have a structure-converting action to an activated form in order to exert infectivity.
- the present inventors have searched for a substance that inhibits the influenza virus activating effect of miniplasmin, that is, a miniplasmin inhibitor, and have found that it can be used as a pharmaceutical. It was found that it was effective in searching for a substance having an anti-influenza virus effect.
- the present invention is characterized in that miniplasmin is used as a probe.
- the present invention relates to a method for searching for a substance having an anti-influenza virus activity. Further, the present invention provides a method for reacting a substance to be detected with miniplasmin as a probe and Sendai virus or influenza virus as a substrate, and using the amount of subunit of the outer membrane glycoprotein precursor of the substrate virus in the reaction solution as an index.
- the present invention relates to a method for searching for a substance having an anti-influenza virus activity.
- the present invention relates to a method for reacting a substance to be investigated with miniplasmin as a probe, using Sendai virus or influenza virus as a substrate, and reacting the substrate virus after the reaction with dog kidney cells (Mard in Darby canine kidney, (Hereinafter abbreviated as “MDCK cells”).
- MDCK cells Mard in Darby canine kidney, (Hereinafter abbreviated as “MDCK cells”).
- miniplasmin which is mainly formed in a local area where neutrophils have leached in large quantities due to a pathological condition such as inflammation, adheres to and exists on a local cell membrane, and Is infected with an influenza virus, the non-infectious influenza virus or non-infectious Sendai virus that grows and germinates from inside the cell can be infected with miniplasmin that can infect cells in the respiratory tract. It has been found that it has the effect of converting it to a virus.
- the present inventors can establish a method for searching for a specific inhibitor for miniplasmin by utilizing this characteristic of miniplasmin, if the drug discovered by the method can be used, influenza virus associated with various inflammatory reactions We thought it would be possible to stop the spread of the infection.
- the details are as follows.
- the present inventors have found that, compared to plasmin, as shown in Table 1, the remarkably hydrophobic nature of plasmin as compared to plasmin, the plasmin force produced by human granulocyte-derived elastase It was predicted that, due to the increased number of cells, they would easily adhere to the surface of various cell membranes and, as a result, would be critically involved in the degradation of proteins, that is, the conversion of viruses to infectious forms.
- influenza virus and Sendai virus that grow by infecting the respiratory tract are infected.
- Influenza virus the outer membrane glycoprotein precursor hemagglutinin (HA) is converted to the hemagglutinin 1 subunit ( ⁇ ,).
- Guruchinin 2 subunit (HA 2) the Sendai virus Tilia one John protein is the outer membrane glycoprotein precursor (F.) is Fusion Protein 1 Sabuyu knit (F and winter one John protein 2 subunit (F 2)
- it must be cleaved by the protease of the host, because the cleavage of the outer membrane glycoprotein precursor only allows the virus to exhibit membrane fusion and infectivity to cells.
- miniplasmin degrades the outer membrane glycoproteins of these viruses to a limited extent, resulting in membrane fusion and infectivity. It was examined whether it is involved in expression. It was revealed that the outer membrane glycoprotein was limitedly degraded, and the non-infectious virus was infected and showed infectivity.
- a substance to be examined for anti-influenza virus activity is introduced into a reaction system containing human miniplasmin and its substrate, for example, Sendai virus or influenza virus, and reacted.
- influenza virus when influenza virus is used as a substrate in the reaction vessel, hemagglutinin 1 (HA and hemagglutinin 2 ( ⁇ ⁇ ,)) generated by cleavage of hemagglutinin (HA), a precursor of its outer membrane glycoprotein.
- HA hemagglutinin 1
- ⁇ ⁇ , hemagglutinin 2
- the Sendai virus is used as a substrate, the presence of the (F) and (F 2 ) subunits caused by cleavage of the outer membrane glycoprotein precursor (F fl ) Analyze whether to do.
- the infectivity titer of cells when infecting MDCK cells with influenza virus may be used.
- a substance to be tested for the presence or absence of anti-influenza virus activity is introduced into a reaction system containing human miniplasmin and its substrate influenza virus, and the reaction is carried out. The virus is removed, MDCK cells are infected, the number of infected cells is detected with a fluorescently labeled anti-influenza antibody, and the CIU is calculated.
- the method for searching for a miniplasmin inhibitor using an artificial substrate as an index as shown in Table 3 is compared with the method for searching using a protein or an actual virus as a substrate.
- ⁇ indicates an artificial substrate with high specificity 3 Inhibitor specificity of human minebrasmin
- ⁇ indicates an inhibitor that showed strong inhibition
- ⁇ indicates an inhibitor that became more inhibitory by increasing the concentration
- Figure 1 shows the results of SDS-polyacrylamide gel electrophoresis of the purified human myniplasmin.
- miniplasmin showed an almost single protein band of about 36-38 kDa, and in the presence of a reducing agent, separated into two protein bands of 28 kDa and 12 kDa. From this fact, it was revealed that miniplasmin has an S—S bond between a 28 kDa protein and a 12 kDa protein. After 28 kDa and 12 kDa protein bands were plotted on the PVDF membrane, the amino acid sequence of about 20 residues was analyzed from each N terminal.
- the 12 kDa protein band showed the sequence of VVAPPPVVLLPNVETPSEED—
- the 28 kDa protein band showed the sequence of VVGGCVAHPHSWP WD VSLRY—.
- the human granulocyte was treated with Erasase, the protein bands of 12 kDa and 28 kDa showed exactly the same amino acid sequence.
- Miniplasmin thus obtained differs in various properties from plasmin. As shown in Table 1, the molecular weight of miniplasmin decreases from 94 kDa to 38 kDa because it lacks the Kringle 1 to 4 region (angiostin) present on the N-terminal side of plasmin. And the hydrophobicity increases significantly. As a result, miniplasmin binds tightly to the cell membrane surface, such as 0.5M NaCl or 0.5% Triton X (trade name: Sigma polyoxyethylene octyl ether). It changes so that it cannot be solubilized unless a surfactant is used.
- Triton X trade name: Sigma polyoxyethylene octyl ether
- microplasmin excluding miniplasmin excluding K ring 1 e5 becomes extremely unstable in the neutral pH range, and its activity is reduced to 50% or less by autolysis within a few minutes.
- miniplasmin is unstable for several hours under the same conditions Activity is maintained.
- Table 2 shows the substrate properties of human miniplasmin.
- the artificial substrates of various trypsin type proteases the artificial substrate Boo-G1u-Lys-Lys-MCA of plasmin, in particular, showed the highest cleavage activity.
- Glu (G1u) —X—Arg which is the same type as the cleavage site recognition amino acid sequence (cleavage motif) commonly found in human influenza viruses reported so far, For the artificial substrate group having the sequence, after Arg was cleaved well.
- the artificial substrate Boc—I1e—G1y—Arg—MCA of factor Xa a proteolytic enzyme that exhibits trypsin-like activity as one of the blood coagulation factors, and one of the lysosomal enzymes
- the catabsin B artificial substrate Bz-Arg-MCA showed almost no cleavage activity.
- Table 3 shows the inhibitory specificity of hitomiplasmin.
- aprotinin AproUnine
- Kunitz-type soybean trypsin inhibitor Yuichi
- Bowman Burk trypsin inhibitor Yuichi
- anti-leukoprotease also known as MPI or SLPI
- benzomidine which inhibits the activity of trypsin, is highly inhibited at high concentrations such as 1 mM to 1 OmM in the case of phenyl fluorosulfonate and phenylmethylsulfonyl fluoride. Showed activity.
- the infectious titer (CIU) of the cells when MDCK cells were infected with influenza virus treated with miniplasmin was examined (Fig. 4). Specifically, non-infectious influenza A / Aichi / 2/68 (H3N2) strains were treated with various concentrations of miniplasmin at 37 in the presence of PBS for 15 minutes, and then the virus was transferred to MDCK cells. And the number of infected cells was detected with a fluorescently labeled anti-influenza AZA ichi / 2/68 (H 3 N 2) antibody to calculate CIU.
- miniplasmin As a result, a remarkable increase in the infectious titer was observed depending on the concentration of miniplasmin, and reached a plateau at 10,4 mU / m 1 or more.
- the activity of miniplasmin shown here was defined as 1 unit with an enzyme that decomposes the artificial substrate B0c-G1u-A1a-Arg-MCA by 1 mol per minute.
- FIG. 1 shows the results of electrophoresis measurement showing SDS-PAGE of human miniplasmin.
- FIG. 2 shows the primary of human plasminogen and human miniplasmin It is a figure showing a structure.
- Figure 3 shows HA and Sendai virus F of influenza AZA iCh i / 2/68 caused by miniplasmin.
- 4 shows the results of an electrophoresis measurement showing limited decomposition of.
- Uninfected influenza A / Aichi / 2/68 / H3N2
- various concentrations of miniplasmin ((), or 20 mU / ml miniplasmin is added to a final concentration of 1 M biprotinin ( ⁇ )
- FITC fluorescent dye labeled anti-influenza A / Aichi antibody.
- Figure 5 shows the purified enzyme preparation using [ 3 H] -labeled Sendai virus as a substrate.
- the supernatant was applied to a soybean trypsin inhibitor sepharose 4B column to absorb miniplasmin, and after sufficient washing, the adsorbed portion was treated with 5 OmM glycine-hydrochloric acid buffer (PH2.8). /0.5 ⁇ Na C 1 This was applied to a gel filtration HPLC column (Superdex200: trade name, manufactured by Amersham Pharmacia Biotech) to remove impurities, and a final sample was obtained.
- PH2.8 OmM glycine-hydrochloric acid buffer
- 3 L of a 3 L concentrated sample buffer for electrophoresis (6% SDS, 30% glycerol, 0.2 M Tris-HCl buffer, pH 6.8) was added to the reaction solution 10 three times. Heat treatment was immediately performed at 100 ° C for 5 minutes. The samples were then run on a 10-20% gradient SDS-polyacrylamide gel and electrophoresed. Electrophoresis was performed at 30 mA per polyacrylamide gel for 2 hours. After electrophoresis, fix the SDS-polyacrylamide gel in a fixing solution (methanol 50%, acetic acid 50%) for 1 hour, and then use a sensitizing solution (Amplify: trade name: Amersham Life Science) for 20 minutes. Processed.
- a fixing solution methanol 50%, acetic acid 50%
- the autoradiograph was RX-U (trade name: manufactured by Fuji Photo Film Co., Ltd.), exposed to light at -80 for 3 days, developed and fixed. , It became a row the detection of FF 2 band.
- Benzamidine was added to the same reaction system as in Example 1, it was treated 37 with 3 hours, was confirmed by the method described the presence of Sabuyuni' Bok bets F 2 in the reaction system in Example 1.
- a sample of miniplasmin (944 mU / mg) was added to the non-infectious influenza AZA ichi Z2Z68 (H 3 N 2) strain in the presence of PBS at 37 ° C for 15 minutes (0, 1.2, 5.
- Each infectivity showed (0 (undetectable values), 1 X 1 0 6, 1. 3 X 1 0 7, 7. 5 X 1 0 7, 9. 6 X 1 0 7) CIU.
- IM aprotinin (Aprotinin) was added to miniplasmin (10.4 mUZm 1), which showed a plateau, treated at 37 ° C for 15 minutes, and CIU was treated in the same manner as above. Was calculated.
- miniplasmin As a probe, a substance having an anti-influenza virus effect can be efficiently searched in vitro.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001523867A JP4579474B2 (ja) | 1999-09-13 | 2000-09-13 | 抗インフルエンザウイルス作用を有する物質の探索方法 |
CA002384821A CA2384821A1 (en) | 1999-09-13 | 2000-09-13 | Method for finding substance having anti-influenza virus activity |
AU73116/00A AU7311600A (en) | 1999-09-13 | 2000-09-13 | Method of searching for substance having anti-influenza virus effect |
EP00960976A EP1215499A4 (en) | 1999-09-13 | 2000-09-13 | METHOD FOR SEARCHING FOR A SUBSTANCE FOR CONTROLLING INFLUENZA VIRUS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25937299 | 1999-09-13 | ||
JP11/259372 | 1999-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001020332A1 true WO2001020332A1 (fr) | 2001-03-22 |
Family
ID=17333218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/006255 WO2001020332A1 (fr) | 1999-09-13 | 2000-09-13 | Procede de recherche d'une substance permettant de lutter contre le virus de la grippe |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1215499A4 (ja) |
JP (1) | JP4579474B2 (ja) |
AU (1) | AU7311600A (ja) |
CA (1) | CA2384821A1 (ja) |
WO (1) | WO2001020332A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007068497A (ja) * | 2005-09-09 | 2007-03-22 | Nihon Pharmaceutical Co Ltd | プラスミンの精製法 |
-
2000
- 2000-09-13 EP EP00960976A patent/EP1215499A4/en not_active Withdrawn
- 2000-09-13 WO PCT/JP2000/006255 patent/WO2001020332A1/ja not_active Application Discontinuation
- 2000-09-13 AU AU73116/00A patent/AU7311600A/en not_active Abandoned
- 2000-09-13 CA CA002384821A patent/CA2384821A1/en not_active Abandoned
- 2000-09-13 JP JP2001523867A patent/JP4579474B2/ja not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
HIROSHI KIDO ET AL.: "Influenza virus tu sendai virus kansen wo seigyo suru saibousei protease to protease inhibitor", KAGAKU RYOUHOU NO RYOUIKI, vol. 15, no. 2, 1999, pages 42 - 51, XP002935191 * |
See also references of EP1215499A4 * |
ULLA CHIRSTENSEN ET AL.: "Enzymic properties of the neo-plasmin-val-442", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 567, 1979, pages 472 - 481, XP002935190 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007068497A (ja) * | 2005-09-09 | 2007-03-22 | Nihon Pharmaceutical Co Ltd | プラスミンの精製法 |
Also Published As
Publication number | Publication date |
---|---|
EP1215499A4 (en) | 2004-11-17 |
EP1215499A1 (en) | 2002-06-19 |
CA2384821A1 (en) | 2001-03-22 |
JP4579474B2 (ja) | 2010-11-10 |
AU7311600A (en) | 2001-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1362127B1 (en) | Serpin drugs for treatment of hiv infection and method of use thereof | |
JP2971034B2 (ja) | リンパ節症/後天性免疫不全症候群ウイルスの抗原 | |
JP7116823B2 (ja) | 新規なトリプシンアイソフォームおよびそれらの使用 | |
JP5437378B2 (ja) | ヒャッポダ由来のヘモコアグラーゼ | |
York et al. | An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion | |
Kido et al. | Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus | |
EP2680876B1 (fr) | Facteur xa depourvu de domaine gla pour le traitement des hemophilies a ou b avec ou sans anticorps | |
EP3737407A1 (en) | Peptides having protease activity for use in the treatment or prevention of coronavirus infection | |
Ranasinghe et al. | A novel coagulation inhibitor from Schistosoma japonicum | |
EA017957B1 (ru) | Композиции и способы, ингибирующие грипп | |
Oubahmane et al. | Host cell proteases mediating SARS-CoV-2 entry: An overview | |
Gaedigk-Nitschko et al. | Cleavage of recombinant and cell derived human immunodeficiency virus 1 (HIV-1) Nef protein by HIV-1 protease | |
WO2001020332A1 (fr) | Procede de recherche d'une substance permettant de lutter contre le virus de la grippe | |
JPH02500408A (ja) | ヒト免疫不全ウイルス特異性プロテアーゼ並びにその合成及び再生方法 | |
US9782472B2 (en) | Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity | |
Tan et al. | Snake venom L-amino acid oxidases and their potential biomedical applications | |
US7479538B2 (en) | Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV | |
Lotke et al. | Restriction of Viral Glycoprotein Maturation by Cellular Protease Inhibitors | |
Ringe | [10] X-ray structures of retroviral proteases and their inhibitor-bound complexes | |
Bahbouhi et al. | Effects of L-and D-REKR amino acid-containing peptides on HIV and SIV envelope glycoprotein precursor maturation and HIV and SIV replication | |
JPH0673092A (ja) | レトロウイルスプロテアーゼ阻害剤 | |
CN109554427B (zh) | 蚓激酶中的一种同工酶切割HBeAg的方法及其治疗乙肝的用途 | |
WO2011057160A2 (en) | Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120 | |
EP0379295A2 (en) | Anti-tryptase antibody and composition for treatment of AIDS using the same | |
CN104311644B (zh) | 多肽、提高多肽稳定性的方法、药物组合物以及多肽在制备药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 523867 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2384821 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000960976 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000960976 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10070921 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000960976 Country of ref document: EP |